IP Library › Granted Patent US 11,306,355
Granted Patent B2
US 11,306,355 · App. 17/201,825 · Granted Apr 19, 2022

Bisulfite-free, base-resolution identification of cytosine modifications

Inventors: Chunxiao Song (Oxford, GB); Yibin Liu (Oxford, GB)
Assignee: Ludwig Institute for Cancer Research Ltd
C12Q1/6869C12P17/16C12Q1/6844C12Q1/6874C12Q1/6876C12Q2600/154C12Y204/01026C12Y204/01027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,306,355
App. No.
17/201,825
Granted
Apr 19, 2022
Kind
B2
Abstract

This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.

Claims (22)

1. A method for identifying 5-methylcytosine (5mC) or 5-hydroxymethylcytosine (5hmC) in a target nucleic acid comprising the steps of:

providing a nucleic acid sample comprising the target nucleic acid;

modifying the target nucleic acid comprising the steps of:

converting the 5mC and 5hmC in the nucleic acid sample to 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC) by contacting the nucleic acid sample with a ten-eleven translocation (TET) enzyme so that one or more 5caC or 5fC residues are generated; and

converting the 5caC and/or 5fC to dihydrouracil (DHU) by treating the target nucleic acid with a borane reducing agent to provide a modified nucleic acid sample comprising a modified target nucleic acid; and

detecting the sequence of the modified target nucleic acid;

wherein a cytosine (C) to thymine (T) transition or a cytosine (C) to DHU transition in the sequence of the modified target nucleic acid compared to the target nucleic acid provides the location of either a 5mC or 5hmC in the target nucleic acid.

2. The method of claim 1 , wherein the borane reducing agent is 2-picoline borane.

3. The method of claim 1 , wherein the step of detecting the sequence of the modified target nucleic acid comprises one or more of chain termination sequencing, microarray, high-throughput sequencing, and restriction enzyme analysis.

4. The method of claim 1 , wherein the TET enzyme is selected from the group consisting of human TET1, TET2, and TET3; murine Tet1, Tet2, and Tet3; Naegleria TET (NgTET); and Coprinopsis cinerea (CcTET).

5. The method of claim 1 , further comprising a step of blocking one or more modified cytosines.

6. The method of claim 5 , wherein the step of blocking comprises adding a sugar to a 5hmC.

7. The method of claim 1 , wherein the method further comprises a step of amplifying the copy number of one or more nucleic acid sequences.

8. A method for chemically modifying a nucleic acid sample comprising the steps of:

providing a nucleic acid sample comprising 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC); and

converting the 5caC and/or 5fC to dihydrouracil (DHU) by treating the nucleic acid with a borane reducing agent to provide a modified nucleic acid sample comprising a modified nucleic acid.

9. The method of claim 8 , wherein the borane reducing agent is selected from the group consisting of 2-picoline borane (pic-BH3), borane, sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride.

10. The method of claim 8 , wherein the borane reducing agent is 2-picoline borane.

11. The method of claim 8 , further comprising the step of detecting the sequence of the modified nucleic acid.

12. The method of claim 11 , wherein the step of detecting the sequence of the modified nucleic acid comprises one or more of chain termination sequencing, microarray, high-throughput sequencing, and restriction enzyme analysis.

13. The method of claim 11 , wherein the sequencing step provides a quantitative level of one or more cytosine modifications in the nucleic acid sample.

14. The method of claim 8 , wherein the method further comprises a step of amplifying the copy number of one or more nucleic acid sequences.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2022
From: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
To: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
Reel/Frame 058812/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2022
From: SONG, CHUNXIAO; LIU, YIBIN
To: THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Reel/Frame 058795/0136 →
Continuity (5)
Continuation 16960510
Provisional Application 62771409 · Nov 26, 2018
Provisional Application 62660523 · Apr 20, 2018
Provisional Application 62614798 · Jan 8, 2018
Related Publication 20210317519A1 · Oct 14, 2021
Cited By (2)
US 12,601,006 US 12,630,866